Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YK012 in Moderate to Severe Systemic Lupus Erythematosus
NCT07010835Phase 2Recruiting
- Sponsor
- Excyte Biopharma Ltd
- Start
- Aug 2025
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of YK012 in systemic lupus erythematosus (SLE), sponsored by Excyte Biopharma Ltd. Started Aug 2025; status: recruiting.
02
Drugs
YK012
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07010835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07010835.